p53 and Bcl-2expression in response to boldenone induced liver cells injury

Toxicology and Industrial Health

Volumn 27, Issue 8, 2011, Pages 711-718

  Tousson, Ehab ^a   Alm Eldeen, Abeer ^a   El Moghazy, Mostafa ^b  

^a Tanta University   (Egypt)

^b Minufiya Government   (Egypt)

Author keywords

apoptosis; boldenone; immunohistochemistry; liver; p53 and Bcl 2 expression

Indexed keywords

BOLDENONE UNDECENOATE; OLIVE OIL; PROTEIN BCL 2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL DAMAGE; LIVER SINUSOID; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RABBIT; TISSUE SECTION;

ANIMALS; APOPTOSIS; CASE-CONTROL STUDIES; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; LIVER; PROTO-ONCOGENE PROTEINS C-BCL-2; RABBITS; TESTOSTERONE; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 80054767626     PISSN: 07482337     EISSN: None     Source Type: Journal    
DOI: 10.1177/0748233710395350     Document Type: Article

References (40)

1. Appella E. (2001) “Modulation of p53 function in cellular regulation. ” European Journal of Biochemistry, 268(10): 2763.
2. Bahrke MS, Yesalis CE, Kopstein AN, and Stepkens JA (2000) Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Medicine, 29: 397-405.
3. Bancroft JD and Cook HC (1994) Manual of Histological Techniques and their Diagnostic Application. 2nd ed. Edinburgh : Churchill Livingstone, 23-26.
4. Borner C. (2003) “The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions.” Molecular Immunology, 39(11): 615-647.
5. Brookhouse B. (2007) Two More Positive Drug Tests. In Fight World”. bloodyelbow.com. Available at http://www.bloodyelbow.com/story/2007/8/17/02615/9740
6. Cannizzo TF, Zancanaro G., Spada F., Mulasso C., Biolatti B. (2007) Pathology of the Testicle and Sex Accessory Glands Following the Administration of Boldenone and Boldione as Growth Promoters in Veal Calves. J Vet Med Sci, 69(11): 1109-1116.
7. Collavin L., Lunardi A., and Del-Sal G. (2010) p43-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death and Differentiation, 17: 901-911.
8. Cory S. and Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer, 2: 647-656.
9. Alix F. De La Costa,McDonel N., Porteu A., Gilgenkrantz H., Perret C., Kahn A., and Mignon A. (1999) Differential protective effects of Bcl-xL and Bcl-2 on apoptotic liver injury un transgenic mice. American Journal of Physiology-Gastrointestestinal and Liver Physiology, 277(3): 702-708.
10. Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, and McConathy WJ (1999) Anabolic steroidinduced hepatotoxicity: is it overstated? Clinical Journal of Sports Medicine, 9: 34-39.
11. Forbes GB (1985) The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism, 34: 571-573.
12. Gabr F., Abo El-Maaty T., Amal M., and Aotifa AM (2009) Effects of growth promoter Boldenone undecylenate on weaned male lambs. Nature and Science, 7(3): 61-69.
13. Hartgens F. and Kuipers H. (2004) Effects of androgenic-anabolic steroids in athletes. Sports Medicine, 34: 513-554.
14. Haupt S., Berger M., Goldberg Z., and Haupt Y. (2003) Apoptosis - the p53 network. Journal of Cell Science, 116: 4077-4085.
15. Hoffmann U. (2002) Anabolic steroids - a problem in popular sports. Toxichem Krimtech, 69(3): 136-142.
16. Hughes TK, Fulep E., Juelich T., Smith EM, and Stanton GJ (1995) Modulation of immune responses by anabolic androgenic steroids. International Journal of Immunopharmacology, 17: 857-863.
17. Jin S. and Levine AJ (2001) The p53 functional circuit. Journal of Cell Sciences, 114: 4139- 4140.
18. Kroemer G., Zamzami N., and Susin SA (1997) “Mitochondrial control of apoptosis. ” Immunology Today, 18 (1): 44-51.
19. Kuwana T., Mackey M.R., Perkins G., Ellisman M.H., Latterich M., Schneiter R., et al. (2002) Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell, 111: 331-342.
20. Kuhn CM (2002) Anabolic steroids. Recent Progress in Hormone Research, 57: 411-434.
21. Levine AJ (1997) p53, the cellular gatekeeper for geowth abd division. Cell, 88: 323-331.
22. Mooradian AD, Morley JE, and Korenman SG (1987) Biological actions of androgens. Endocrine Reviews, 8: 1-28.
23. Nagatu S. (1997) Apoptosis by death factor. Cell, 88: 355-365.
24. Rolland SG and Conradt B. (2010) New role of the BCL2 family of proteins in the regulation of mitochondrial dynamics. Current Opinion in Cell Biology, 22(6): 852-858.
25. Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, and Celermajer DS (2001) Androgenic anabolic steroids and arterial structure and function in male body builders. J American College of Cardiology, 37: 224-230.
26. Schänzer W. (1996) Metabolism of anabolic androgenic steroids. Clinical Chem, 42: 1001-1020.
27. Schänzer W. and Donike M. (1992) Metabolism of boldenone in man Gas chromatographic/mass spectrometric identification of urinary excreted metabolites and determination of excretion rates. Biological Mass Spectrometry, 21: 3-16.
28. Scorrano L. and Korsmeyer SJ (2003) “Mechanisms of cytochrome c release by proapoptotic BCL-2 family members.” Biochemical and Biophysical Research Communications, 304(3): 437-44.
29. Soma LR, Uboh CE, Guan F., MC-Donnell S., and Pack J. (2007) Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. Journal of Veterinary Pharmacology and Therapeutics, 30: 101-108.
30. Sternberger LA (1979) The unlabelled antibody peroxidase- antiperoxidase (PAP) method. In: Cohen S, McClusky RT (eds). Immunocytochemistry. 2nd ed. New York: John Wiley and sons, 104-169.
31. Sullivan ML, Martinez CM, Gennis P., and Gallagher EJ (1998) The cardiac toxicity of anabolic steroids. Progress in Cardiovascular Diseases, 41: 1-15.
32. Sundlof SF (2001) Legal control of veterinary drugs. In Adams HR (ed.) Veterinary Pharmacology Therapeutics. 8th edn, Ames, IA: Iowa State University Press, 1155.
33. Vaux DL and Strasser (1996) The molecular biology of apoptosis. Proceedings of the National Academy of Sciences USA, 93: 2239-2244.
34. Teale P. and Houghton E. (1991) The development of a gas chromatographic/mass spectrometric screening procedure to detect the administration of anabolic steroids to the horse. Biological Mass Spectrometry, 20: 109 114.
35. Thierry S. (2000) The p53 tumor suppressor gene: from molecular biology to clinical investigation. Annals of New York Academy of Sciences, 910: 121-137.
36. Welder AA, et al. (1995) Toxic effects of anabolic-androgenic steroids in primary rat hepatic cultures. Journal of Pharmacology and Toxicological Methods, 33: 187-95.
37. Yesalis CE, Bahrke MS, Kopstein AN, and Kennedy NJ (2000) Incidence of anabolic steroid use. A discussion of methodological issues. In: Yesalis CE (ed). Anabolic Steroids in Sport and Exercise. 2nd ed. Champaign, IL, 73-115.
38. Yesalis CE, Kennedy NJ, Kopstein AN, and Bahrke MS (1993) Anabolic-androgenic steroid use in the United States. Journal of the American Veterinary Medical Association, 270: 1217-1221.
39. Yonish-Rouach E., Grunwald D., Wilder S., Kimchi A., May E., Lawrence JJ, et al (1993) p53-mediated cell death: relationship to cell cycle control. Molecular Cell Biology, 13: 1415-1423.
40. Wang L., Bowman L., Lu Y., Rojanasakul Y., Mercer RR, Castranova V., and Ding M. (2005) Essential role of p53 in silica-induced apoptosis. American Journal of Physiology, 288: 488-496.